SCHEMBL20156788

SCHEMBL20156788

CCN1C(=O)C(=C/C=C/c2cc#ccc2)C(=O)N(CC)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.42
ALDH1A1 P00352 10/20 0.42
KMT2A Q03164 9/20 0.42
MEN1 O00255 7/20 0.42
POLB P06746 5/20 0.42
L3MBTL1 Q9Y468 4/20 0.42
HPGD P15428 4/20 0.42
HTT P42858 3/20 0.42
MDM2 Q00987 3/20 0.42
THRB P10828 2/20 0.42
KDM4E B2RXH2 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
APP P05067 5/20 0.35
SNCA P37840 4/20 0.35
MAPK1 P28482 4/20 0.34
MITF O75030 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
PKM P14618 1/20 0.34
F2 P00734 1/20 0.32
ELANE P08246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14712967 0.80 MAPT (0.53) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL14713067 0.69 MEN1 (0.81) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL14712965 0.69 MAPT (0.64) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL14712876 0.68 MAPT (0.59) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL14712905 0.67 MAPT (0.57) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL14712957 0.67 MAPT (0.57) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL20243251 0.65 APP (0.52) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL16543009 0.65 MAPT (0.55) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL14712975 0.65 METAP1 (0.56) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL14712869 0.64 BCL2A1 (0.61) MAPTALDH1A1KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MAPT 2828/4885ALDH1A1 186/4885KMT2A 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.